JP2022523763A5 - - Google Patents
Info
- Publication number
- JP2022523763A5 JP2022523763A5 JP2021547557A JP2021547557A JP2022523763A5 JP 2022523763 A5 JP2022523763 A5 JP 2022523763A5 JP 2021547557 A JP2021547557 A JP 2021547557A JP 2021547557 A JP2021547557 A JP 2021547557A JP 2022523763 A5 JP2022523763 A5 JP 2022523763A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cells
- subject
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805052P | 2019-02-13 | 2019-02-13 | |
| US62/805,052 | 2019-02-13 | ||
| PCT/US2020/018127 WO2020168090A1 (en) | 2019-02-13 | 2020-02-13 | Cancer immunotherapy using combinations of cells expressing chimeric antigen receptors and monoclonal antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022523763A JP2022523763A (ja) | 2022-04-26 |
| JP2022523763A5 true JP2022523763A5 (https=) | 2023-02-20 |
Family
ID=72045642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547557A Pending JP2022523763A (ja) | 2019-02-13 | 2020-02-13 | キメラ抗原受容体を発現する細胞とモノクローナル抗体との組み合わせを用いたがん免疫療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220168343A1 (https=) |
| EP (1) | EP3924372A4 (https=) |
| JP (1) | JP2022523763A (https=) |
| KR (1) | KR20210131365A (https=) |
| AU (1) | AU2020221271A1 (https=) |
| CA (1) | CA3127142A1 (https=) |
| WO (1) | WO2020168090A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG187991A1 (en) * | 2002-05-02 | 2013-03-28 | Wyeth Corp | Calicheamicin derivative-carrier conjugates |
| AU2012351728A1 (en) * | 2011-12-16 | 2014-06-19 | Oncology Institute Of Southern Switzerland | Combination of inotuzumab ozogamicin and torisel for the treatment of cancer |
| ES2878449T3 (es) * | 2014-07-24 | 2021-11-18 | 2Seventy Bio Inc | Receptores antigénicos quiméricos de BCMA |
| JP6961490B2 (ja) * | 2015-04-08 | 2021-11-05 | ノバルティス アーゲー | Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法 |
| AU2016274989A1 (en) * | 2015-06-12 | 2017-11-02 | Immunomedics, Inc. | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs |
-
2020
- 2020-02-13 AU AU2020221271A patent/AU2020221271A1/en not_active Abandoned
- 2020-02-13 KR KR1020217029189A patent/KR20210131365A/ko not_active Ceased
- 2020-02-13 EP EP20756013.7A patent/EP3924372A4/en active Pending
- 2020-02-13 US US17/430,540 patent/US20220168343A1/en not_active Abandoned
- 2020-02-13 WO PCT/US2020/018127 patent/WO2020168090A1/en not_active Ceased
- 2020-02-13 CA CA3127142A patent/CA3127142A1/en active Pending
- 2020-02-13 JP JP2021547557A patent/JP2022523763A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cang et al. | Novel CD20 monoclonal antibodies for lymphoma therapy | |
| ES2563439T5 (es) | Medios y métodos para tratar LDCBG | |
| JP6177133B2 (ja) | Ｃｄ３８を特異的に認識する抗体とボルテゾミブを含有する抗腫瘍性の組合せ | |
| JP6215429B2 (ja) | Ｃｄ３８を特異的に認識する抗体とシクロホスファミドとを含有する抗腫瘍組合せ | |
| JP2023516936A5 (https=) | ||
| TWI549690B (zh) | 包含抗－ｃｄ１９類美登素（ｍａｙｔａｎｓｉｎｏｉｄ）免疫結合物及利妥昔單抗（ｒｉｔｕｘｉｍａｂ）之用於治療ｃｄ１９＋ｂ－細胞惡性症狀之組合療法 | |
| TW201806616A (zh) | 抗－ｐｄ－１抗體與輻射治療癌症之組合 | |
| JP2019515008A5 (https=) | ||
| JP2008530142A5 (https=) | ||
| JP2015205893A (ja) | Ｃｄ３８を特異的に認識する抗体とシタラビンを含有する抗腫瘍性組合せ剤 | |
| US20200353077A1 (en) | Combinations and uses thereof | |
| JP2021525735A (ja) | 抗ｃｄ３７免疫コンジュゲート投薬レジメン | |
| JP2019508433A (ja) | Ｌｉｖ１−ａｄｃ及び化学療法剤を用いた併用療法 | |
| Dias et al. | Novel therapeutic strategies in acute lymphoblastic leukemia | |
| JP2026001086A (ja) | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 | |
| US20200102399A1 (en) | Methods of Treating Peripheral T Cell Lymphoma Using Anti-CD30 Antibody Drug Conjugate Therapy | |
| WO2017210621A1 (en) | Combination of cd33 antibody drug conjugates with chemotherapeutic agents | |
| JP2015516980A (ja) | Ｃｄ３７抗体とベンダムスチンとの併用 | |
| EP3442591A1 (en) | Combinations of cd33 antibody drug conjugates with hypomethylating agents | |
| JP2020516613A5 (https=) | ||
| JP2022523763A5 (https=) | ||
| TW202028248A (zh) | 使用抗ｃｄ１２３免疫結合物之治療方法 | |
| TW202034925A (zh) | Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途 | |
| JP7659546B2 (ja) | 造血器がんの治療のための抗ｃｄ３０ ａｄｃ、抗ｐｄ－１、および化学療法剤の併用 | |
| Siddiqi et al. | Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia: Part 1: monoclonal antibodies. |